This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Will This Coverage Initiation Help MannKind (MNKD) Stock Today?

NEW YORK (TheStreet) -- MannKind Corp. (MNKD) had coverage initiated on its shares with a "market perform" rating by Brinson Patrick. The firm set a price target of $12 on the shares.

MannKind stock is up 1.0% to $6.45 in premarket trading Tuesday.

Brinson Patrick believes that the biotech company's Afrezza drug will eventually be approved by the FDA and sees the focus of investors shifting from regulation concerns to business concerns. 

 Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

"We have a high level of conviction for approval. We view the votes and recommendations as a best-case-scenario for Afrezza, and envision a major partnership announcement soon," analysts said.

"We see little risk to approval, despite the PDUFA extension. With much of the approval risk behind Afrezza, we see investor focus shifting to labeling, commercial partnership, and successful launch," the note continued. "We expect the initial demand for Afrezza to be high considering statements made by the panel and open public hearing about its efficacy, safety, pharmacokinetics, and attractive size."

MNKD Chart

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
MNKD $5.30 -5.00%
AAPL $125.94 -0.52%
FB $86.76 -0.17%
GOOG $522.08 0.05%
TSLA $275.10 2.20%

Markets

DOW 17,697.18 -60.73 -0.34%
S&P 500 2,072.39 -5.03 -0.24%
NASDAQ 4,992.9620 -20.1610 -0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs